SCHEMBL4469971

SCHEMBL4469971

Cc1cc2ccccc2c(=O)n1-c1ccc(O)cc1

nearest known ligand 0.51

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.51
MEN1 O00255 2/20 0.48
KMT2A Q03164 2/20 0.48
POLB P06746 1/20 0.48
KLK7 P49862 1/20 0.48
MAPK1 P28482 3/20 0.46
LMNA P02545 2/20 0.46
GRM1 Q13255 1/20 0.46
ESR1 P03372 2/20 0.46
HSD17B10 Q99714 2/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
ESR2 Q92731 1/20 0.43
THRB P10828 1/20 0.42
KDM4E B2RXH2 1/20 0.42
NPSR1 Q6W5P4 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
MAPT P10636 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28127253 0.83 ALDH1A1 (0.48) ALDH1A1MEN1KMT2APOLBKLK7
SCHEMBL4472902 0.83 LMNA (0.65) ALDH1A1MEN1KMT2APOLBLMNA
SCHEMBL16596826 0.82 CA1 (0.49) ALDH1A1MEN1KMT2AMAPK1LMNA
SCHEMBL76833 0.78 ESR2 (0.47) ALDH1A1KMT2AESR1SMN1; SMN2ESR2
SCHEMBL28113666 0.75 ALDH1A1 (0.56) ALDH1A1MEN1KMT2AKLK7LMNA
SCHEMBL16596824 0.74 LMNA (0.48) ALDH1A1LMNAHSD17B10SMN1; SMN2KDM4E
SCHEMBL1436331 0.74 ERCC1 (0.44) ALDH1A1KMT2APOLBLMNAHSD17B10
SCHEMBL2118476 0.73 MAPK1 (0.76) ALDH1A1MEN1KMT2APOLBKLK7
Hydrochloric Acid SCHEMBL5468118 0.72 POLB (0.63) ALDH1A1MEN1KMT2APOLBMAPK1
SCHEMBL13180854 0.72 HSD17B10 (0.53) ALDH1A1KMT2APOLBLMNAHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1717230-B1 FUSED-RING 4-OXOPYRIMIDINE DERIVATIVE MSD KK (JP) 2014-08-06 EP disclosed
US-8268842-B2 Fused ring 4-oxopyrimidine derivative MSD K.K. (JP) 2012-09-18 US disclosed
US-20090209562-A1 Fused ring 4-oxopyrimidine derivative BANYU PHARMACEUTICAL CO., LTD. (JP) 2009-08-20 US disclosed
US-7521455-B2 Fused ring 4-oxopyrimidine derivative BANYU PHARMACEUTICAL CO. LTD. (JP) 2009-04-21 US disclosed
EP-1717230-A1 FUSED-RING 4-OXOPYRIMIDINE DERIVATIVE BANYU PHARMACEUTICAL CO., LTD. (JP) 2006-11-02 EP disclosed
US-20050182045-A1 Fused ring 4-oxopyrimidine derivative BANYU PHARMACEUTICAL CO., LTD. (JP) 2005-08-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050182045-A1 Fused ring 4-oxopyrimidine derivative HRH4, HRH2, HRH3 ALDH1A1 1717/4885MEN1 2904/4885KMT2A 528/4885
US-20090209562-A1 Fused ring 4-oxopyrimidine derivative HRH4, HRH2, HRH3 ALDH1A1 1717/4885MEN1 2904/4885KMT2A 528/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.